Introduction
Immunization is a fundamental part of pediatric healthcare and has significantly improved standards of international public health. Previous studies demonstrate intensive chemotherapy may cause notable decreases in vaccine-specific antibody titers in childhood cancer survivors (CCS). 1-6
In CCS, the loss of protective antibodies poses a risk from vaccine-preventable infections well after immune reconstitution.7 These potentially life-threatening infections represent an avoidable source of morbidity and mortality and may create potential disease vectors that threaten public health initiatives.
While there are published guidelines for the revaccination of hematopoietic stem cell transplant (HSCT) patients, there are no unified guidelines for the revaccination of CCS not undergoing HSCT.8,9 Vaccine-specific titer data for CCS has been limited to studies with low sample sizes and conflicting conclusions.10-13 More vaccine-specific titer data is needed to build standardized guidelines for this vulnerable population.